Wet Age Related Macular Degeneration (AMD) Market, Global Outlook and Forecast 2022-2028

March 2022 | 63 pages | ID: W54F50D54B0DEN
Market Monitor Global

Abstracts

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.

This report contains market size and forecasts of Wet Age Related Macular Degeneration (AMD) in Global, including the following market information:

Global Wet Age Related Macular Degeneration (AMD) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Wet Age Related Macular Degeneration (AMD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Wet Age-Related Macular Degeneration (Wet AMD) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Wet Age Related Macular Degeneration (AMD) include Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada) and F. Hoffmann-La Roche (Switzerland), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Wet Age Related Macular Degeneration (AMD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Wet Age Related Macular Degeneration (AMD) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages, by Type, 2021 (%)

• Wet Age-Related Macular Degeneration (Wet AMD)
• Dry Age-Related Macular Degeneration (Dry AMD)

Global Wet Age Related Macular Degeneration (AMD) Market, by Age, 2017-2022, 2023-2028 ($ millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages, by Age, 2021 (%)

• Above 75 Years
• Above 60 Years
• Above 40 Years

Global Wet Age Related Macular Degeneration (AMD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Wet Age Related Macular Degeneration (AMD) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Wet Age Related Macular Degeneration (AMD) revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Wet Age Related Macular Degeneration (AMD) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novartis International (Switzerland)
• Bayer (Germany)
• Acucela (US)
• Neurotech Pharmaceuticals (US)
• Ophthotech (US)
• GlaxoSmithKline (US)
• Alimera Sciences (US)
• StemCell (Canada)
• F. Hoffmann-La Roche (Switzerland)
• Regeneron Pharmaceutical (US)
• Allergan (Ireland)
• Adverum Biotechnologies (US)
• Gilead Sciences (US)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Wet Age Related Macular Degeneration (AMD) Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Age
1.3 Global Wet Age Related Macular Degeneration (AMD) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL WET AGE RELATED MACULAR DEGENERATION (AMD) OVERALL MARKET SIZE

2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size: 2021 VS 2028
2.2 Global Wet Age Related Macular Degeneration (AMD) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Wet Age Related Macular Degeneration (AMD) Players in Global Market
3.2 Top Global Wet Age Related Macular Degeneration (AMD) Companies Ranked by Revenue
3.3 Global Wet Age Related Macular Degeneration (AMD) Revenue by Companies
3.4 Top 3 and Top 5 Wet Age Related Macular Degeneration (AMD) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Wet Age Related Macular Degeneration (AMD) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Players in Global Market
  3.6.1 List of Global Tier 1 Wet Age Related Macular Degeneration (AMD) Companies
  3.6.2 List of Global Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Wet Age Related Macular Degeneration (AMD) Market Size Markets, 2021 & 2028
  4.1.2 Wet Age-Related Macular Degeneration (Wet AMD)
  4.1.3 Dry Age-Related Macular Degeneration (Dry AMD)
4.2 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts
  4.2.1 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022
  4.2.2 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028
  4.2.3 By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Wet Age Related Macular Degeneration (AMD) Market Size, 2021 & 2028
  5.1.2 Above 75 Years
  5.1.3 Above 60 Years
  5.1.4 Above 40 Years
5.2 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts
  5.2.1 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022
  5.2.2 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028
  5.2.3 By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Wet Age Related Macular Degeneration (AMD) Market Size, 2021 & 2028
6.2 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue & Forecasts
  6.2.1 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2022
  6.2.2 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue, 2023-2028
  6.2.3 By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028
  6.3.2 US Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.3.3 Canada Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.3.4 Mexico Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028
  6.4.2 Germany Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.3 France Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.4 U.K. Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.5 Italy Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.6 Russia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.7 Nordic Countries Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.4.8 Benelux Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028
  6.5.2 China Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.5.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.5.4 South Korea Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.5.5 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.5.6 India Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028
  6.6.2 Brazil Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.6.3 Argentina Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028
  6.7.2 Turkey Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.7.3 Israel Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.7.4 Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028
  6.7.5 UAE Wet Age Related Macular Degeneration (AMD) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis International (Switzerland)
  7.1.1 Novartis International (Switzerland) Corporate Summary
  7.1.2 Novartis International (Switzerland) Business Overview
  7.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.1.4 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.1.5 Novartis International (Switzerland) Key News
7.2 Bayer (Germany)
  7.2.1 Bayer (Germany) Corporate Summary
  7.2.2 Bayer (Germany) Business Overview
  7.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.2.4 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.2.5 Bayer (Germany) Key News
7.3 Acucela (US)
  7.3.1 Acucela (US) Corporate Summary
  7.3.2 Acucela (US) Business Overview
  7.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.3.4 Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.3.5 Acucela (US) Key News
7.4 Neurotech Pharmaceuticals (US)
  7.4.1 Neurotech Pharmaceuticals (US) Corporate Summary
  7.4.2 Neurotech Pharmaceuticals (US) Business Overview
  7.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.4.4 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.4.5 Neurotech Pharmaceuticals (US) Key News
7.5 Ophthotech (US)
  7.5.1 Ophthotech (US) Corporate Summary
  7.5.2 Ophthotech (US) Business Overview
  7.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.5.4 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.5.5 Ophthotech (US) Key News
7.6 GlaxoSmithKline (US)
  7.6.1 GlaxoSmithKline (US) Corporate Summary
  7.6.2 GlaxoSmithKline (US) Business Overview
  7.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.6.4 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.6.5 GlaxoSmithKline (US) Key News
7.7 Alimera Sciences (US)
  7.7.1 Alimera Sciences (US) Corporate Summary
  7.7.2 Alimera Sciences (US) Business Overview
  7.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.7.4 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.7.5 Alimera Sciences (US) Key News
7.8 StemCell (Canada)
  7.8.1 StemCell (Canada) Corporate Summary
  7.8.2 StemCell (Canada) Business Overview
  7.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.8.4 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.8.5 StemCell (Canada) Key News
7.9 F. Hoffmann-La Roche (Switzerland)
  7.9.1 F. Hoffmann-La Roche (Switzerland) Corporate Summary
  7.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
  7.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.9.4 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.9.5 F. Hoffmann-La Roche (Switzerland) Key News
7.10 Regeneron Pharmaceutical (US)
  7.10.1 Regeneron Pharmaceutical (US) Corporate Summary
  7.10.2 Regeneron Pharmaceutical (US) Business Overview
  7.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.10.4 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.10.5 Regeneron Pharmaceutical (US) Key News
7.11 Allergan (Ireland)
  7.11.1 Allergan (Ireland) Corporate Summary
  7.11.2 Allergan (Ireland) Business Overview
  7.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.11.4 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.11.5 Allergan (Ireland) Key News
7.12 Adverum Biotechnologies (US)
  7.12.1 Adverum Biotechnologies (US) Corporate Summary
  7.12.2 Adverum Biotechnologies (US) Business Overview
  7.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.12.4 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.12.5 Adverum Biotechnologies (US) Key News
7.13 Gilead Sciences (US)
  7.13.1 Gilead Sciences (US) Corporate Summary
  7.13.2 Gilead Sciences (US) Business Overview
  7.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Major Product Offerings
  7.13.4 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue in Global Market (2017-2022)
  7.13.5 Gilead Sciences (US) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Wet Age Related Macular Degeneration (AMD) Market Opportunities & Trends in Global Market
Table 2. Wet Age Related Macular Degeneration (AMD) Market Drivers in Global Market
Table 3. Wet Age Related Macular Degeneration (AMD) Market Restraints in Global Market
Table 4. Key Players of Wet Age Related Macular Degeneration (AMD) in Global Market
Table 5. Top Wet Age Related Macular Degeneration (AMD) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Wet Age Related Macular Degeneration (AMD) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Wet Age Related Macular Degeneration (AMD) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Wet Age Related Macular Degeneration (AMD) Product Type
Table 9. List of Global Tier 1 Wet Age Related Macular Degeneration (AMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Wet Age Related Macular Degeneration (AMD) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Age – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Age - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Age - Wet Age Related Macular Degeneration (AMD) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2023-2028
Table 30. Novartis International (Switzerland) Corporate Summary
Table 31. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 32. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 33. Bayer (Germany) Corporate Summary
Table 34. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 35. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 36. Acucela (US) Corporate Summary
Table 37. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 38. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 39. Neurotech Pharmaceuticals (US) Corporate Summary
Table 40. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 41. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 42. Ophthotech (US) Corporate Summary
Table 43. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 44. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 45. GlaxoSmithKline (US) Corporate Summary
Table 46. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 47. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 48. Alimera Sciences (US) Corporate Summary
Table 49. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 50. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 51. StemCell (Canada) Corporate Summary
Table 52. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 53. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 54. F. Hoffmann-La Roche (Switzerland) Corporate Summary
Table 55. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 56. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 57. Regeneron Pharmaceutical (US) Corporate Summary
Table 58. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 59. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 60. Allergan (Ireland) Corporate Summary
Table 61. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 62. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 63. Adverum Biotechnologies (US) Corporate Summary
Table 64. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 65. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)
Table 66. Gilead Sciences (US) Corporate Summary
Table 67. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product Offerings
Table 68. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Wet Age Related Macular Degeneration (AMD) Segment by Type in 2021
Figure 2. Wet Age Related Macular Degeneration (AMD) Segment by Age in 2021
Figure 3. Global Wet Age Related Macular Degeneration (AMD) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Wet Age Related Macular Degeneration (AMD) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Wet Age Related Macular Degeneration (AMD) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Wet Age Related Macular Degeneration (AMD) Revenue in 2021
Figure 8. By Type - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 9. By Age - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 12. US Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 16. Germany Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 17. France Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 24. China Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 28. India Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 30. Brazil Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Wet Age Related Macular Degeneration (AMD) Revenue Market Share, 2017-2028
Figure 33. Turkey Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Wet Age Related Macular Degeneration (AMD) Revenue, (US$, Mn), 2017-2028
Figure 37. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Acucela (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)